Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study

Table 3

Subgroup analysis of time interval from initial dose of oral anticoagulant to discharge in patients with primary discharge diagnosis of PE.

Characteristic	Warfarin plus enoxaparin; median LOS (days); (IQR)	Rivaroxaban; median LOS (days); (IQR)	Interval; value
Age (years)
≥60 (, 33)	3.9 (2.7, 4.9)	0.9 (0.8, 2.1)	<0.001
<60 (, 43)	2.9 (1.6, 4.9)	0.8 (0.2, 1.1)	<0.001
Classification
Stable (, 60)	3.0 (1.9, 4.8)	0.9 (0.5, 1.6)	<0.001
Submassive (, 14)	4.2 (3.0, 6.9)	0.9 (0.5, 2.2)	<0.001
Payer type
Private (, 54)	2.9 (1.8, 4.9)	1.8 (1.5, 2.8)	<0.001
Medicare/Medicaid (, 19)	3.9 (1.9, 5.8)	3.7 (1.8, 4.5)	0.001

= number in warfarin plus enoxaparin group and number in rivaroxaban group, respectively.
CrCl: creatinine clearance; IQR: interquartile range.
Massive PE not included due to low frequency of occurrences.